Analysts See $-0.20 EPS for AquaVenture Holdings Limited (WAAS); Enanta Pharmaceuticals Has 1.29 Sentiment

Analysts expect AquaVenture Holdings Limited (NYSE:WAAS) to report $-0.20 EPS on March, 7.They anticipate $0.05 EPS change or 20.00% from last quarter’s $-0.25 EPS. After having $-0.10 EPS previously, AquaVenture Holdings Limited’s analysts see 100.00% EPS growth. The stock increased 1.66% or $0.35 during the last trading session, reaching $21.4. About 59,980 shares traded. AquaVenture Holdings Limited (NYSE:WAAS) has risen 22.87% since February 13, 2018 and is uptrending. It has outperformed by 22.87% the S&P500. Some Historical WAAS News: 23/03/2018 AquaVenture Holdings Announces ASC 606 Education Session Conference Call; 08/05/2018 – AquaVenture Holdings 1Q Loss/Shr 24c; 14/05/2018 – Fidelity Management & Research Exits Position in AquaVenture; 22/04/2018 – DJ AquaVenture Holdings Limited, Inst Holders, 1Q 2018 (WAAS); 08/05/2018 – AquaVenture Holdings Backs FY18 Adjusted Ebitda $42M-$47M; 08/05/2018 – AQUAVENTURE HOLDINGS- IMPACT OF DEAL WITH ABENGOA WATER TO PURCHASE MAJORITY INTEREST IN DESALINATION PLANT IN ACCRA NOT INCLUDED IN 2018 OUTLOOK; 08/05/2018 – AquaVenture Holdings 1Q Rev $32.5M; 08/05/2018 – AquaVenture Holdings Limited to Participate at Upcoming Investor Conferences; 09/05/2018 – AquaVenture Presenting at Deutsche Bank Conference May 15; 11/05/2018 – Russell Investments Group Buys New 1% Position in AquaVenture

Enanta Pharmaceuticals Inc (ENTA) investors sentiment decreased to 1.29 in 2018 Q3. It’s down -0.21, from 1.5 in 2018Q2. The ratio fall, as 94 active investment managers increased and started new equity positions, while 73 sold and reduced stakes in Enanta Pharmaceuticals Inc. The active investment managers in our database now hold: 16.15 million shares, up from 14.64 million shares in 2018Q2. Also, the number of active investment managers holding Enanta Pharmaceuticals Inc in top ten equity positions decreased from 2 to 1 for a decrease of 1. Sold All: 19 Reduced: 54 Increased: 58 New Position: 36.

More notable recent AquaVenture Holdings Limited (NYSE:WAAS) news were published by: which released: “Consolidated Research: 2019 Summary Expectations for Marathon Petroleum, AMC Entertainment, JetBlue Airways, Acceleron Pharma, Natera, and AquaVenture — Fundamental Analysis, Key Performance Indications – GlobeNewswire” on January 22, 2019, also with their article: “AquaVenture Holdings’s CEO to step down – Seeking Alpha” published on November 02, 2018, published: “AquaVenture Holdings extends long-stop date on Ghanaian acquisition – Seeking Alpha” on September 25, 2018. More interesting news about AquaVenture Holdings Limited (NYSE:WAAS) were released by: and their article: “Tampa’s AquaVenture acquires Illinois company in $57.6M deal – Tampa Bay Business Journal” published on December 18, 2018 as well as‘s news article titled: “AquaVenture Holdings Announces Participation of OPIC and Extension of Long-Stop Date in Ghanaian Acquisition – Business Wire” with publication date: January 02, 2019.

AquaVenture Holdings Limited provides water-as-a-service solutions in North America, the Caribbean, South America, and the Middle East. The company has market cap of $572.05 million. It offers point-of-use filtered water systems and related services to approximately 40,000 institutional and commercial customers; and desalination and wastewater treatment solutions to governmental, municipal, industrial, and hospitality customers. It currently has negative earnings.

More notable recent Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) news were published by: which released: “Enanta Pharmaceuticals FQ3 revenue up 84% – Seeking Alpha” on February 06, 2019, also with their article: “Enanta Pharmaceuticals (ENTA) Earnings Expected to Grow: Should You Buy? – Nasdaq” published on January 30, 2019, published: “Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering – Benzinga” on February 06, 2019. More interesting news about Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) were released by: and their article: “The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings, IPOs (Feb. 3-9) – Benzinga” published on February 03, 2019 as well as‘s news article titled: “Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut – Benzinga” with publication date: February 07, 2019.

Since January 1, 0001, it had 0 insider buys, and 2 sales for $779,632 activity.

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology firm focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company has market cap of $1.87 billion. The companyÂ’s research and development focuses on four disease targets: Hepatitis C virus , Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). It has a 23.25 P/E ratio. The Company’s lead product is paritaprevir, a protease inhibitor designed for use against HCV.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Institutional Positions Chart